Cargando…
443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections
BACKGROUND: Oritavancin (ORI) is a long-acting lipoglycopeptide antibiotic indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible Gram-positive (GP) pathogens. METHODS: Data collected from a retro...
Autores principales: | Redell, Mark, Sierra-Hoffman, Miguel, Assi, Maha, Bochan, Markian, Chansolme, David, Gandhi, Anurag, Sheridan, Kathleen R, Soosaipillai, Ivan, Walsh, Thomas L, Massey, Jill |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810118/ http://dx.doi.org/10.1093/ofid/ofz360.516 |
Ejemplares similares
-
The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019) -
Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes
por: Redell, Mark
Publicado: (2020) -
Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
por: Hoover, Randall K, et al.
Publicado: (2022) -
Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020) -
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)